Nikhitha Mantri

Dr. Nikhitha Mantri

BronxCare Health System
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Western Journal of Emergency Medicine
Verified
Journal Article
Open access
PDF file
SCSridhar Chilimuri
Sridhar Chilimuri
HSHaozhe Sun
Haozhe Sun
AAAhmed Alemam
Ahmed Alemam
NMNikhitha Mantri
Nikhitha Mantri
ESElona Shehi
Elona Shehi
SNSuresh K. Nayudu
Suresh K. Nayudu
Introduction: Rapid spread of coronavirus disease 2019 (COVID-19) in the United States, especially in New York City (NYC), led to a tremendous increase in hospitalizations and mortality. There is very limited data available that associates outcomes during hospitalization in patients with COVID-19.Methods: In this retrospective cohort study, we reviewed the health records of patients with COVID-19 who were admitted from March 9–April 9, 2020, to a community hospital in NYC. Subjects with confirmed reverse transcriptase-polymerase chain reaction (RT-PCR) of the nasopharyngeal swab for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were included. We collected data related to demographics, laboratory results, and outcome of hospitalization. Outcome was measured based on whether the patient was discharged home or died during hospitalization.Results: There were 888 consecutive admissions with COVID-19 during the study period, of which 513 were excluded with pending outcome or incomplete information. We included a total of 375 patients in the study, of whom 215 (57%) survived and 160 (43%) died during hospitalization. The majority of patients were male (63%) and of Hispanic origin (66%) followed by Blacks (25%), and others (9%). Hypertension (60%) stands out to be the most common comorbidity followed by diabetes mellitus (47%), cardiovascular disease (17%), chronic kidney disease (17%), and human immunodeficiency virus/acquired immunodeficiency syndrome (9%). On multiple regression analysis, increasing odds of mortality during hospitalization was associated with older age (odds ratio [OR] 1.04; 95% confidence interval [CI], 1.01-1.06 per year increase; p < 0.0001), admission D-dimer more than 1000 nanograms per milliliter (ng/mL) (OR 3.16; 95% CI, 1.75-5.73; p<0.0001), admission C-reactive protein (CRP) levels of more than 200 milligrams per liter (mg/L) (OR 2.43; 95% CI, 1.36-4.34; p = 0.0028), and admission lymphopenia (OR 2.63; CI, 1.47-4.69; p 0.0010).Conclusion: In this retrospective cohort study originating in NYC, older age, admission levels of D-dimer of more than 1000 ng/mL, CRP of more than 200 mg/L and lymphopenia were associated with mortality in individuals hospitalized for COVID-19. We recommend using these risk factors on admission to triage patients to critical care units or surge units to maximize the use of surge capacity beds.

17 August 2020 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
AHAhmad Hanif
Ahmad Hanif
SKSumera Khan
Sumera Khan
NMNikhitha Mantri
Nikhitha Mantri
SHSana Hanif
Sana Hanif
MSMuhamed Saleh
Muhamed Saleh
KJKevin R. Jain
Kevin R. Jain

4 March 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
SCSridhar Chilimuri
Sridhar Chilimuri
NMNikhitha Mantri
Nikhitha Mantri
SGsudharsan gongati
sudharsan gongati
MZMaleeha Zahid
Maleeha Zahid
HSHaozhe Sun
Haozhe Sun
Vaccines will play a key role in ending the COVID-19 pandemic. Vaccination against infections remains an important part of the management of patients with multiple sclerosis. However, there are limited data about the safety and efficacy of the currently available COVID-19 mRNA vaccines in patients with multiple sclerosis receiving concurrent immunosuppressive therapies. Patients on B cell depleting therapy such as ocrelizumab have an attenuated vaccine response. We report the first case of COVID-19 vaccine failure in a patient with relapsing-remitting multiple sclerosis on B cell depleting therapy, ocrelizumab. We offer suggestions to improve vaccine efficacy in these patients.

1 November 2020 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
DBDiana Maria Ronderos Botero
Diana Maria Ronderos Botero
AOAlaa Mabrouk Salem Omar
Alaa Mabrouk Salem Omar
HSHaozhe Sun
Haozhe Sun
NMNikhitha Mantri
Nikhitha Mantri
KFKed Fortuzi
Ked Fortuzi
SCSridhar Chilimuri
Sridhar Chilimuri
Objective: Coronavirus disease 2019 (COVID-19) can infect patients in any age group including those with no comorbid conditions. Understanding the demographic, clinical, and laboratory characteristics of these patients is important toward developing successful treatment strategies. Approach and Results: In a retrospective study design, consecutive patients without baseline comorbidities hospitalized with confirmed COVID-19 were included. Patients were subdivided into ≤55 and >55 years of age. Predictors of in-hospital mortality or mechanical ventilation were analyzed in this patient population, as well as subgroups. Stable parameters in overall and subgroup models were used to construct a cluster model for phenotyping of patients. Of 1207 COVID-19–positive patients, 157 met the study criteria (80≤55 and 77>55 years of age). Most reliable predictors of outcomes overall and in subgroups were age, initial and follow-up d -dimer, and LDH (lactate dehydrogenase) levels. Their predictive cutoff values were used to construct a cluster model that produced 3 main clusters. Cluster 1 was a low-risk cluster and was characterized by younger patients who had low thrombotic and inflammatory features. Cluster 2 was intermediate risk that also consisted of younger population that had moderate level of thrombosis, higher inflammatory cells, and inflammatory markers. Cluster 3 was a high-risk cluster that had the most aggressive thrombotic and inflammatory feature. Conclusions: In healthy patient population, COVID-19 remains significantly associated with morbidity and mortality. While age remains the most important predictor of in-hospital outcomes, thromboinflammatory interactions are also associated with worse clinical outcomes regardless of age in healthy patients.

5 October 2020 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
Muhammad AdrishMuhammad Adrish
Muhammad Adrish
SCSridhar Chilimuri
Sridhar Chilimuri
NMNikhitha Mantri
Nikhitha Mantri
HSHaozhe Sun
Haozhe Sun
MZMaleeha Zahid
Maleeha Zahid
RSRavish Singhal
Ravish Singhal
Introduction Smoking causes inflammation of the lung epithelium by releasing cytokines and impairing mucociliary clearance. Some studies have linked smoking with severity of illness of COVID-19 whereas others have found no such association. Methods This was a retrospective analysis of all adults hospitalised with COVID-19 from 9 March to 18 May 2020. Results 1173 patients met the study criteria. 837 patients never smoked whereas 336 patients were either current smokers or past smoker and were grouped together in smokers group. Patients in smokers group were more likely to be male and had higher incidence of underlying chronic obstructive pulmonary disease (19% vs 6%, p<0.001), HIV infection (11% vs 5%,p<0.001), cancer (11% vs 6%, p=0.005), congestive heart failure (15% vs 8%, p<0.001), coronary artery disease (15% vs 9%, p=0.3), chronic kidney disease (11% vs 8%, p=0.037) and end-stage renal disease (10% vs 6%, p=0.009) compared with non-smokers. Outcome analysis showed that smokers were more likely to develop critical illness requiring mechanical ventilation (47% vs 37% p=0.005). Univariate Cox model for survival analysis by smoking status showed that among smokers only current smokers had higher risk of death compared with never smokers (HR 1.61, 95% CI 1.22 to 2.12, p<0.001). In the multivariate approach, Cox model for the survival, female sex, young age, low serum lactate dehydrogenase and systemic steroid use were associated with overall improved survival. Conclusion In our large single-centre retrospective database of patients hospitalised with COVID-19, smoking was associated with development of critical illness and higher likelihood of death.

24 October 2020 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
SCSridhar Chilimuri
Sridhar Chilimuri
HSHaozhe Sun
Haozhe Sun
AAAhmed Alemam
Ahmed Alemam
KKKyoung‐Sil Kang
Kyoung‐Sil Kang
PLPeter Lao
Peter Lao
SNSuresh Kumar Nayudu
Suresh Kumar Nayudu
What is known and objective The coronavirus disease 2019 (COVID‐19) associated cytokine activation can lead to a rapid progression into respiratory failure, shock and multiorgan failure. Interleukin‐6 (IL‐6) is a pro‐inflammatory cytokine that likely contributes to the pathogenesis of cytokine release syndrome. It is hypothesized that modulating IL‐6 levels or its effects with tocilizumab, a recombinant humanized anti‐IL‐6 receptor monoclonal antibody, may alter the course of disease. Methods We examined the association between tocilizumab use and intubation or death at a community hospital in New York City. Data were obtained regarding consecutive patients hospitalized with COVID‐19. The primary end point was a composite of intubation or death in a time‐to‐event analysis. We compared outcomes in patients who received tocilizumab with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. Results and Discussion In this single‐centre retrospective cohort study involving 1225 hospitalized patients with SARS‐CoV‐2 infection, the probability to respiratory failure, which was measured as intubation or death, was less frequent in patients who received tocilizumab. What is new and conclusion Tocilizumab and other IL‐6 receptor monoclonal antibodies may evolve as a viable option in treating patients with moderate and severe COVID‐19.